Michael Mülleder

Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity

Abstract Heterobifunctional targeted degraders (HBDs) enable potent removal of protein targets but their clinical success can be hindered by de novo toxicity inherent to their bivalent chemistry. Here we introduce a drug discovery framework that exploits high-throughput proteomic...

Proteome signatures in ICU patients with COVID-19 and acute brain dysfunction: an observational cohort study

Abstract Deep sedation and delirium are common in COVID-19 intensive care unit (ICU) patients. Biomarkers for prediction, detection, and monitoring are missing. Unbiased omics analyses are warranted to gain a systems biology view on pathophysiology. This prospective observational...